Objective: An endogenous digitalis-like factor (EDLF) has been implicated in the pathophysiology of preeclampsia (PE). This hypothesis is supported by two cases of preeclampsia in which administration of digoxin immune Fab (DIF) reduced mean arterial pressure (MAP). Study Design: To study this observation further, we performed a double-blind, placebo-controlled, randomized clinical trial to examine the effects on MAP of intravenous DIF given after delivery in 26 subjects with severe preeclampsia. Treating obstetricians were blinded to subject assignment and were allowed to use standard antihypertensive drugs during the trial. Results: The primary outcome, a significant difference in blood pressure between the two groups over the 24-h period of observation after the intervention, was not supported. However, mean MAP was significantly lower in the DIF-treated subjects for the first 4 h after therapy as compared with controls (P ¼ 0.05). Six subjects (46.2%) in the placebo arm were given conventional antihypertensive medications by their obstetrician for blood pressure >160 mm Hg systolic or >110 mm Hg diastolic, compared with zero subjects in the treatment arm (P ¼ 0.01). A trend towards increased creatinine clearance was observed in DIF-treated subjects (137.6 ± 42.6 versus 104.1 ± 43.4, P ¼ 0.07). Conclusion: These results support the hypothesis that EDLF contributes to the elevated blood pressure in preeclampsia and suggests a possible role for DIF as a treatment for this condition.
Introduction
Preeclampsia is the second leading cause of premature birth and accounts for a significant percentage of maternal morbidity and mortality. 1 Despite the significance of preeclampsia in clinical obstetrics, no etiology has been elucidated which fully explains its clinical manifestations, of which hypertension is paramount.
Endogenous digitalis-like factor (EDLF) has been postulated to contribute to the elevation of blood pressure in several hypertensive states including various animal models and a human essential hypertension model. [2] [3] [4] In 1984, two groups demonstrated increased circulating levels of an endogenous factor that crossreacted with digoxin antibodies in preeclampsia. 5, 6 This observation, and the demonstration that digoxin antiserum lowered blood pressure in animal models of hypertension, 7 led Goodlin 8 to propose the use of a commercially available, ovine, digoxinbinding Fab fragment immunoglobulin (Digibind, Glaxo Wellcome/Smith Kline Beecham) (DIF) as a treatment for the elevated blood pressure of preeclampsia. Goodlin 9 reported that DIF lowered blood pressure in his index subject, and we reported similar results in one additional subject. 10 Because of these encouraging findings, we performed a prospective, randomized, double-blind, placebo-controlled trial of the effect of DIF on blood pressure in subjects with severe preeclampsia. To avoid fetal exposure to the unknown effects of DIF, the study drug was administered during the immediate postpartum period. This strategy, used by other investigators, takes advantage of the fact that blood pressure does not normalize immediately after delivery. 1 
Materials and methods
Twenty-six subjects with the diagnosis of severe preeclampsia as defined by the American College of Obstetrics and Gynecology 11 were enrolled in this IRB approved study conducted between September 1995 and May 1996 at The Wake Forest University School of Medicine. Subjects were recruited and signed a consent document prior to commencement of the delivery process. Baseline measurements were made during the four-hour period immediately prior to active intervention towards delivery. All subjects were free of any chronic medical illnesses, particularly chronic hypertension, renal disease, and autoimmune disorders. No participant had received digoxin. Subjects who intended to breast-feed were not enrolled. If the subject decided to breast-feed after enrollment, they were asked to abstain from breast-feeding for a 24-h period after the therapeutic intervention.
Subjects were randomized to receive either DIF or a matched placebo of normal saline. The dose of Digibind was calculated based on the manufacturer's recommendations assuming an EDLF level of 2.0 ng per ml and using the subject's weight at delivery (Dose ¼ 2 Â subject weight in kg/100). 12 Within 15 min of the clamping of the umbilical cord after delivery, DIF or normal saline was administered as an intravenous bolus over 10 min. Subject surveillance included hourly serial blood pressure measurement and mean arterial pressure (MAP) determination and urinary output collection by Foley catheter for 24 h postpartum. The blood pressure was obtained with subjects in the left lateral recumbent position using an automated sphygmomanometer (Critikon Dinamap, Model no. 1846, Critikon Inc. Tampa, Florida, USA). The mean arterial pressure was calculated as {[systolic blood pressure þ (2 Â diastolic blood pressure)]C3}. A complete blood count and serum electrolyte panel were obtained within the 2-h period prior to delivery (baseline), and repeated at 24-h postdelivery. A urine collection for creatinine clearance and protein and calcium excretion was obtained during the 24 h immediately after delivery.
Fluid intakes and outputs were carefully recorded and included blood and blood products. All subjects received freshly prepared lactated Ringer's solution at 75 ml per h and magnesium sulfate at 50 ml per h (2 g per h) prior to initiation of delivery and during the 24 h post-delivery. All clinical decisions were made by attending obstetricians and included method of delivery, use of antenatal steroids, and the selection and administration of antihypertensive drugs before and after randomization. Although no strict criteria for use of antihypertensive drugs were developed a priori, subjects who received them usually had systolic blood pressure >160 mm Hg, and/or diastolic blood pressure >110 mm Hg. All clinicians and individuals recording clinical parameters were blinded to subject assignment. No adverse events were noted, and the randomization code remained unbroken throughout the study.
Statistical methods
The primary outcome was the difference in MAP between the placebo (normal saline) and treatment (DIF) groups over the 24 h period after administration of the study drug. The a priori hypothesis was that DIF administration would decrease the mean arterial pressure in subjects with severe preeclampsia.
Randomization was performed by assistance of a computergenerated randomization list using a permuted block design to ensure equal numbers of participants. The randomization list was maintained by a research nurse who was responsible for preparation of the study solutions in an area separate from the labor and delivery suite.
Descriptive statistic frequencies for categorical variables and means with s.d. for continuous data were generated for the two groups. Categorical data were analyzed by Fisher's exact test, or w 2 , where appropriate. Continuous variables were analyzed by a Student's t-test. Repeated measures analysis of covariance adjusting for baseline MAP using maximum likelihood estimation was used to assess differences in blood pressure between the two treatment regimens. Results with a P-value equal to or less than 0.05 were considered significant; no adjustments were made for multiple comparisons. A log-rank approximation of the w 2 test was used to evaluate a time-to-event analysis, in which subjects were considered to be event-free until the first occurrence of a drop of 5 or 10 mm Hg in systolic or diastolic blood pressure.
Results
Twenty-six subjects were enrolled in the trial, 13 subjects to each study arm. The demographics of the two groups are presented in Table 1 . No differences were noted with respect to age, parity, race, or method of delivery. Seven subjects in each group were given steroids before delivery. There was no significant difference in frequency of diagnostic criteria for severe preeclampsia between DIF and placebo groups (blood pressure >160/110, 38.5 versus 46.2%; proteinuria >5.0 g/24 h, 46.2 versus 23.1%; and CNS irritability, 15.3 versus 30.7%).
Mean baseline MAP in the placebo group (111.3 ± 11.2 mm Hg) was higher than mean baseline MAP in the DIF group Digoxin binding antibody in severe preeclampsia CD Adair et al (105.3±4.7) therefore, adjustment for baseline MAP was included in all repeated measures models. For the primary outcome, no difference in mean MAP relative to baseline was apparent between the two groups over the entire 24-h period after delivery (P ¼ 0.15), and there was no significant interaction between treatment group and time effect. However, post hoc analyses revealed a significant effect in the first few hours after the intervention in each treatment group as shown in Figure 1 . Analyses were performed sequentially for each of these hours such that all data points from the first hour to the hour being analyzed were included. Using this approach, a significant treatment effect is seen at 4 h, with a larger decrease in mean MAP in the DIF-treated group (P ¼ 0.05). In addition, there were borderline effects in mean MAP between the two groups at two (P ¼ 0.09), three (P ¼ 0.052), and five (P ¼ 0.09) hours after treatment. No significant differences in mean MAP were noted for any other hourly time period after treatment. Figure 2 shows the results of the time-to-event analysis (fall in systolic blood pressure of 5 mm Hg). There is a significant difference in the event times between the two groups for systolic blood pressure (P ¼ 0.004). The DIF group had a median time of 1 h until the first event, whereas the placebo group had a median time of 5 h. Eight of the subjects receiving DIF experienced the drop in the first hour whereas five of the placebo subjects did not experience a similar change within the first 6 h. There was no difference between the two groups for fall in systolic blood pressure of 10 mm Hg, or for fall in diastolic blood pressure.
As noted in Methods, the protocol allowed obstetricians who were blinded to subject assignment to use antihypertensive agents during the trial to ameliorate hypertension. Six subjects (42.6%) in the placebo group were given antihypertensive drugs during the first 6 h postpartum for elevated blood pressures, versus none in the DIF-treated group (P<0.01). These same six subjects required further antihypertensive therapy 24 h post-delivery for persistent elevation of blood pressure (systolic >160 mm Hg and/or diastolic >110 mm Hg). Conversely, none of the DIF-treated subjects required antihypertensive medications during the 24 h following study drug administration.
Laboratory values in each group are shown in Table 2 . No differences between groups were noted at entry. However, 24 h after delivery, serum magnesium levels were lower in DIF-treated subjects (4.2 ± 0.8 mEq per L versus 5.5 ± 1.9 mEq per L, P ¼ 0.01). Postpartum serum glucose values were significantly lower for DIF versus placebo subjects (90.2 ± 14.4 versus 105.3±19.6 mg per dL, P<0.05) and a trend for higher creatinine Figure 1 Mean arterial pressure is shown for the two treatment groups at baseline, and for each of the first six hours after the intervention. Data are means±one standard deviation. Figure 2 Time to 5 mmHg decrease in systolic blood pressure for the first six hours after DIF administration is shown. The difference between the two groups is significant (p<0.004). Table 2 Laboratory values in randomized subjects Digoxin binding antibody in severe preeclampsia CD Adair et al clearance in the DIF group (137.6 ± 42.6 ml per minute versus 104.1±43.4 ml per minute, P ¼ 0.07) was noted. There were no differences between groups pre and post therapy for liver function, uric acid and platelet values. The total volume intake was the same in DIF and placebo-treated subjects for the 24 h postpartum (5203.4±1764.9 ml in DIF, versus 5117.1±1640.7 ml in placebo, P ¼ 0.91). Urine output was also not different (DIF 4103.1 ± 2253.9 ml per 24 h, versus placebo 4307.2 ± 1610.03 ml per 24 h, P ¼ 0.73). Importantly, no adverse events were noted in any subject.
Discussion
The hypothesis that EDLF contributes to the blood pressure elevation in preeclampsia is controversial. Although there is general agreement that a substance that cross reacts with digoxin antibodies is present in maternal blood during the third trimester of pregnancy, not all studies have shown that blood levels are higher in patients with preeclampsia when compared with patients with normal pregnancies. 5, 6, [13] [14] [15] [16] [17] [18] The strongest evidence for a causal role of EDLF in preeclampsia is the anecdotal reports that digoxin-binding immunoglobulin lowers blood pressure in preeclampsia. 9, 10 The present trial represents the next step in formally evaluating the role of EDLF and attenuation of EDLF in the preeclamptic patient.
We recognize that this trial has a number of limitations, not the least of which is that the study was performed in the postpartum, as necessitated by safety considerations. Previous research demonstrates that the EDLF is cleared rapidly from maternal plasma after delivery, with greater than 90% of it no longer detectable 24 h post partum. 19 This would suggest a biological half life of approximately 6 h, that is, half of the EDLF would be cleared from maternal circulation during the first 6 h post-delivery. Of interest, this is the period where the blood pressure differences were evident in this study, suggesting not only that the DIF Fab fragment binds and 'neutralizes' the EDLF but also that the EDLF is being rapidly cleared. If this EDLF mediates the hypertension of many women with PE as these and other studies suggest, then the DIF will at best hasten the decrease of EDLF and speed the normalization of the blood pressure in the post partum period. The results of the time-to-event analysis support this conclusion. Clearly, evaluation of treatment during the antepartum period is of great interest and importance.
A second limitation of the study was the use of antihypertensive medications in some subjects. Blood pressure medications were necessary in 6 of 13 subjects receiving placebo because of continued marked elevations or spikes in their blood pressure (blood pressure equal to or greater than 160 mm Hg systolic and/or 110 mm Hg diastolic). In fact, antihypertensive drugs were given to six subjects in the placebo group and none in the treatment group (P ¼ 0.01). The use of these medications solely in the placebo subjects could have diminished or negated blood pressure differences between the two study groups. However, even though no one in the treatment group required an antihypertensive, this group demonstrated a significantly lower mean MAP at 3 and 4 h and over the first 4 h after DIF administration. There was also a trend toward lower mean MAPs at 2 and 5 h post intervention in the treatment group. These results support previous anecdotal observations that DIF lowers blood pressure in patients with preeclampsia, and supports the hypothesis that EDLF contributes to the elevated blood pressure.
A third potential limitation is the dose of DIF used. The dose effect of DIF for this clinical application has never been evaluated, and it is possible that a larger effect on blood pressure might be observed with a higher dose of DIF. It is unlikely that the blood pressure lowering effect of DIF was due to an anaphylactoid response to the antibody, although we did not specifically analyze for evidence of anaphylactoid markers. DIF is lacking the immunogenic Fc portion, and there have been no reports of anaphylactoid reactions to DIF administration despite thousands of individuals having received it. If an anaphylactoid reaction was responsible for the fall in blood pressure, it should have occurred earlier than we observed.
Systemic steroids have been shown to lower postpartum blood pressure in preeclampsia complicated by elevated liver enzymes, low platelets and hemolysis (HELLP Syndrome). 20 As antenatal steroids were given to an equal number of subjects in each study arm it is unlikely this treatment would have affected the trial outcome. Furthermore, patients with HELLP were specifically excluded from study participation.
Current evidence indicates the existence of at least two classes of mammalian digitalis-like factors, analogous to cardenolides found in plants and the bufadienolides found in toads. 21, 22 These two classes differ structurally in the number of atoms in the lactone ring located at the C17 position on the steroid nucleus; there being a 5-membered ring in plant-derived and a 6-membered ring in toad-derived sodium pump inhibitors. One mammalian digitalislike factor analogous to plant-derived cardenolides is similar if not identical to natural ouabain (OB). 23, 24 One mammalian factor, marinobufagenin (MBG) is analogous to toad-derived bufadienolides. 25 Using antibodies specific for each of these compounds, elevated levels of OB and MBG, as measured by radioimmunoassay of both, have been shown in preeclampsia. 26 As both OB and MBG cross-react with digoxin antibodies, 22 the lowering of blood pressure we observed with DIF could have been due to binding of one or both endogenous cardenolides by the digoxin antibody or possibly, to an as yet unidentified EDLF. It should be noted, however, that in vitro cross reactivity of digoxin antibodies to MBG is about 50 times higher than to OB. 22 The tissue origin of EDLF in normal pregnancies and preeclampsia is not entirely clear. The rapid disappearance of EDLF from maternal blood postpartum, and its presence for several days after birth in fetal blood suggest a placental origin; 27 however, this was not found in two other studies. 28, 29 Some form of EDLF has been extracted from placental tissue, 30, 31 and in one study, an MBG-like factor was tentatively identified. 32 The demonstration that immediate curettage accelerates the recovery from preeclampsia 33 further suggests that the placenta contributes significantly to the abnormal pathophysiology of preeclampsia, possibly by secreting EDLF.
We observed two other interesting responses to DIF treatment. First, serum magnesium levels 24 h postpartum were different between the two groups. Baseline serum magnesium levels were comparably elevated in both groups because they were receiving magnesium sulfate infusions at the institutional standard of 6 g load and 2 g per hour intravenously. Twenty-four hours after delivery serum magnesium rose in the placebo group, but did not rise in the treatment group. Interestingly, this effect is similar to that seen when DIF was given to rats with experimental, acute myocardial infarction, 34 and suggests that reversal of Na K ATPase inhibition may affect magnesium metabolism. In addition, in the treatment group renal clearance of magnesium may have been greater. The explanation for these opposing changes in magnesium among the two groups remains to be determined.
Finally, we observed an approximate 25% increase in creatinine clearance in subjects treated with DIF. Although this change was of borderline statistical significance, it is similar to the increase in creatinine clearance we observed in a patient with preeclampsia treated with DIF prior to delivery. 10 The exact mechanism of this effect is not known, but is compatible with reversal of intrarenal vasoconstriction by DIF.
Preeclampsia is a generalized disorder characterized by increased peripheral vascular resistance, altered endothelial function and a variety of other abnormalities, 1, 35 the pathophysiology of which is not known. EDLF could contribute to the increased peripheral resistance by increasing the sympathetic tone and/or by a direct effect to increase vascular smooth muscle contraction. 2 Interestingly, increased sympathetic tone has been demonstrated in preeclampsia. 35 EDLF in the plasma would not be expected to directly cause other associated abnormalities observed in patients with preeclampsia, such as altered endothelial cell function. 36 It is possible, however, that release of factors that induce these endothelial abnormalities is secondary to a primary increase in maternal circulating level of EDLF originating in the fetoplacental unit.
In conclusion, our data in this small trial suggest that DIF might be useful in the treatment of preeclampsia in the early postpartum period in cases in which the blood pressure remains elevated. The absence of adverse effects in this trial, and in the previous anecdotal reports, suggests that DIF could also be used for treating preeclampsia prior to delivery, and a randomized controlled clinical trial has recently been completed in antepartum subjects. 37 
